trial

An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With Schizophrenia

NCTId NCT00728195
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 498 (actual)
Sponsored by Johnson & Johnson
Primary completion 2010-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
498 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2008-11
Primary completion
2010-02
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
JNJ-37822681Olanzapine

Sponsors

Johnson & JohnsonLead Sponsor

Sites

0 total

Linked catalysts

1
An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants Wi — primary completion2010-02

Facts & assertions

4 sourced
Enrollment
498
Phase
PHASE2
Primary Completion Date
2010-02
Status
COMPLETED
relationships
The graph out of here
drug
JNJ-37822681
drug
Olanzapine
drug
lead_sponsor
Johnson & Johnson
company
indication
Schizophrenia
indication
Schizophrenia
indication